Foresite Capital Management IV

Latest statistics and disclosures from Foresite Capital Management IV's latest quarterly 13F-HR filing:

  • Top 5 stock holdings are KNTE, LYEL, PHVS, ACRS, KURA, and represent 88.09% of Foresite Capital Management IV's stock portfolio.
  • Reduced shares in these 3 stocks: ACRS (-$8.6M), HLTH, NRIX.
  • Foresite Capital Management IV was a net seller of stock by $-16M.
  • Foresite Capital Management IV has $357M in assets under management (AUM), dropping by -26.45%.
  • Central Index Key (CIK): 0001704132

Tip: Access up to 7 years of quarterly data

Positions held by Foresite Capital Management IV consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Portfolio Holdings for Foresite Capital Management IV

Companies in the Foresite Capital Management IV portfolio as of the March 2022 quarterly 13F filing

Company (Ticker) Portfolio Weight Valued At Change in Shares Share Count Share Price
Kinnate Biopharma (KNTE) 30.5 $109M 9.7M 11.26
Lyell Immunopharma (LYEL) 18.8 $67M 13M 5.05
Pharvaris N V (PHVS) 16.5 $59M 3.3M 18.14
Aclaris Therapeutics (ACRS) 14.0 $50M -14% 2.9M 17.24
Kura Oncology (KURA) 8.3 $30M 1.8M 16.08
Quantum-Si Incorporated Com Cl A (QSI) 5.8 $21M 4.5M 4.68
Nurix Therapeutics (NRIX) 4.0 $14M -14% 1.0M 14.01
Cymabay Therapeutics (CBAY) 1.6 $5.6M 1.8M 3.11
Cue Health (HLTH) 0.5 $1.7M -73% 264k 6.45

Past Filings by Foresite Capital Management IV

SEC 13F filings are viewable for Foresite Capital Management IV going back to 2017

View all past filings